Clinical trial Recruiting at 1 site Observational Ages 19 and up Women only

Maternal and infant microbiome links to infant gut inflammation and pregnancy outcomes in people with IBD

Official title: Exploring the Gut Microbiota and Dietary Contributors to Elevated Infant Fecal Calprotectin In Patients With Inflammatory Bowel Disease: A Pilot Study (CALINA-IBD)

Run by University of British Columbia · NCT07385807 · Data updated 2026-11-12

This project will see if mothers' microbiomes, diets, and breastmilk are linked to infant gut inflammation (measured by fecal calprotectin) in pregnant people with and without IBD.

More Pregnancy trials

Quick facts

Study typeObservational
Ages19 Years and up
SexWomen only
Enrollment80 (estimated)
SponsorUniversity of British Columbia
Academic / other
Locations2 sites (Vancouver, British Columbia and 1 other locations)
StatusRecruiting
StartedMarch 20, 2026
Main results expectedFebruary 1, 2028
Study endsFebruary 1, 2028
Registry record updatedApril 6, 2026
Trial IDNCT07385807 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Pregnant individuals aged 19 or older in the first, second, or early third trimester, with or without a documented diagnosis of IBD, who can provide serial biological samples and use a compatible smartphone app for dietary tracking are ideal candidates.

Probably not a fit

People who are under 19, not pregnant, or who have exclusionary conditions such as prior gastrointestinal cancer or bowel surgery, major immune-mediated diseases, recent probiotic use, or serious infection are excluded and unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective longitudinal cohort that follows pregnant individuals with and without IBD and their infants through pregnancy and the first year of life. Participants provide serial fecal samples, one third-trimester vaginal swab, breastmilk, and dietary data via a smartphone app, and infants' fecal calprotectin (FCP) is measured as a marker of gut inflammation. The study compares microbiome compositions, human milk oligosaccharides (HMOs), and dietary patterns between IBD and non-IBD dyads and tracks associations with elevated infant FCP. Researchers will also attempt to build and validate a machine-learning model to predict high infant FCP at 1 year from maternal and infant microbiome and dietary data.

Why it matters

Potential benefit: If successful, the findings could identify maternal or infant microbiome and dietary factors that point to dietary or breastfeeding interventions to reduce infant gut inflammation and potentially lower later risk of allergy or IBD.

How similar studies have gone: Prior observational research has linked maternal microbiota and infant fecal calprotectin to later allergic and IBD risk, but combining detailed microbiome, HMO profiling, dietary data, and machine-learning prediction in pregnancy is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

All patients

* Pregnant individuals ≥19 years recruited during their first, second or early third trimester.
* Own or have regular access to a smartphone compatible with the study smartphone application RXFood.

IBD patients

● A documented IBD diagnosis (CD or UC) with active or quiescent disease.

Non-IBD controls ● Absence of IBD.

Exclusion Criteria:

All patients

* Inability to provide consent
* Previous gastrointestinal cancer or bowel surgery
* Renal disease
* HIV/AIDS or other serious infection
* Fetal chromosomal or structural abnormalities
* Other immune-mediated diseases (e.g., multiple sclerosis, rheumatoid arthritis, primary sclerosing cholangitis)
* Prebiotic, probiotic or postbiotic supplements in the month prior to first sample collection
* Gastroenteritis during or 1 month before the first sample collection
* Travel outside of Canada and the United States in the month prior to first sample collection

IBD patients

● Pregnant individuals with active perianal or extra-intestinal disease in IBD

Where it's running

  • BC Children's Hospital Research Institute
    Vancouver, British Columbia, Canada
    Recruiting
  • BC Children's Hospital Research Institute
    Vancouver, British Columbia, Canada
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.